Lipid-Polymer Hybrid Nanoparticles for Controlled Delivery of Hydrophilic and Lipophilic Doxorubicin for Breast Cancer Therapy

Show full item record



Permalink

http://hdl.handle.net/10138/304493

Citation

Tahir , N , Madni , A , Correia , A , Rehman , M , Balasubramanian , V , Khan , M M & Santos , H A 2019 , ' Lipid-Polymer Hybrid Nanoparticles for Controlled Delivery of Hydrophilic and Lipophilic Doxorubicin for Breast Cancer Therapy ' , International Journal of Nanomedicine , vol. 14 , pp. 4961-4974 . https://doi.org/10.2147/IJN.S209325

Title: Lipid-Polymer Hybrid Nanoparticles for Controlled Delivery of Hydrophilic and Lipophilic Doxorubicin for Breast Cancer Therapy
Author: Tahir, Nayab; Madni, Asadullah; Correia, Alexandra; Rehman, Mubashar; Balasubramanian, Vimalkumar; Khan, Muhammad Muzamil; Santos, Hélder A.
Contributor: University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, Drug Research Program
Date: 2019-07-05
Language: eng
Number of pages: 14
Belongs to series: International Journal of Nanomedicine
ISSN: 1178-2013
URI: http://hdl.handle.net/10138/304493
Abstract: Background: Lipid polymer hybrid nanoparticles (LPHNPs) for the controlled delivery of hydrophilic doxorubicin hydrochloride (DOX.HCl) and lipophilic DOX base have been fabricated by the single step modified nanoprecipitation method. Materials and methods: Poly (D, L-lactide-co-glicolide) (PLGA), lecithin, and 1,2-distearoyl-Sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000 (DSPE-PEG 2000) were selected as structural components. Results: The mean particle size was 173–208 nm, with an encapsulation efficiency of 17.8±1.9 to 43.8±4.4% and 40.3±0.6 to 59. 8±1.4% for DOX.HCl and DOX base, respectively. The drug release profile was in the range 33–57% in 24 hours and followed the Higuchi model (R2,=0.9867–0.9450) and Fickian diffusion (n<0.5). However, the release of DOX base was slower than DOX.HCl. The in vitro cytotoxicity studies and confocal imaging showed safety, good biocompatibility, and a higher degree of particle internalization. The higher internalization of DOX base was attributed to higher permeability of lipophilic component and better hydrophobic interaction of particles with cell membranes. Compared to the free DOX, the DOX.HCl and DOX base loaded LPHNPs showed higher antiproliferation effects in MDA-MB231 and PC3 cells. Conclusion: Therefore, LPHNPs have provided a potential drug delivery strategy for safe, controlled delivery of both hydrophilic and lipophilic form of DOX in cancer cells
Subject: CO-DELIVERY
CONTROLLED-RELEASE
CURCUMIN
DRUG-DELIVERY
EFFICACY
ENHANCED ANTITUMOR-ACTIVITY
FORMULATION
HEPATOCELLULAR-CARCINOMA
IN-VITRO
SILICA NANOPARTICLES
breast cancer
doxorubicin
drug delivery
lipid polymer hybrid
nanotechnology
317 Pharmacy
221 Nano-technology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
ijn_209325.pdf 2.221Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record